Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study Meeting Abstract
| Authors: | Vogel, A.; Chan, S. L.; Furuse, J.; Tak, W. Y.; Masi, G.; Varela, M.; Kim, J. H.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; Makowsky, M.; Marcovitz, M.; Negro, A.; Abou-Alfa, G. K. |
| Abstract Title: | Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study |
| Meeting Title: | Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting |
| Journal Title: | Hepatology |
| Volume: | 76 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Nov 4-8 |
| Meeting Location: | Washington, D.C. |
| ISSN: | 0270-9139 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2022-10-01 |
| Start Page: | S1418 |
| End Page: | S1419 |
| Language: | English |
| ACCESSION: | WOS:000870796604283 |
| PROVIDER: | wos |
| DOI: | 10.1002/hep.32697 |
| Notes: | Meeting Abstract: 4549 -- Meeting also held virtually -- Source: Wos |
